...
首页> 外文期刊>International Journal of Chronic Obstructive Pulmonary Disease >Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction
【24h】

Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction

机译:NT-pro-BNP在无基础左心功能不全的COPD患者急性加重中的意义

获取原文

摘要

Background: B-type natriuretic peptide (BNP) and the N-terminal fragment of pro-BNP (NT-pro-BNP) are established biomarkers of heart failure. Increased levels of natriuretic peptide (NP) have been associated with poor outcomes in acute exacerbation of COPD (AECOPD); however, most studies did not address the conditions that can also increase NT-pro-BNP levels. We aimed to determine if NT-pro-BNP levels correlate with outcomes of AECOPD in patients without heart failure and other conditions that can affect NT-pro-BNP levels. Methods: We conducted a retrospective study in patients hospitalized for AECOPD with available NT-pro-BNP levels and normal left ventricular ejection fraction. We compared patients with normal and elevated NT-pro-BNP levels and analyzed the clinical and outcome data. Results: A total of 167 of 1,420 (11.7%) patients met the study criteria. A total of 77% of male patients and 53% of female patients had elevated NT-pro-BNP levels ( P =0.0031). NT-pro-BNP levels were not associated with COPD severity and comorbid illnesses. Log-transformed NT-pro-BNP levels were positively associated with echocardiographically estimated right ventricular systolic pressure ( r =0.3658; 95% confidence interval [CI]: 0.2060–0.5067; P <0.0001). Patients with elevated NT-pro-BNP levels were more likely to require intensive care (63% vs 43%; P =0.0207) and had a longer hospital length of stay ( P =0.0052). There were no differences in the need for noninvasive positive pressure ventilation ( P =0.1245) or mechanical ventilation ( P =0.9824) or in regard to in-hospital mortality ( P =0.5273). Conclusion: Patients with AECOPD and elevated NT-pro-BNP levels had increased hospital length of stay and need for intensive care. Based on our study, serum NT-pro-BNP levels cannot be used as a biomarker for increased mortality or requirement for invasive or noninvasive ventilation in this group of patients.
机译:背景:B型利钠肽(BNP)和前BNP(NT-pro-BNP)的N端片段是确定的心力衰竭生物标志物。利钠肽(NP)水平升高与COPD急性加重(AECOPD)不良预后相关;但是,大多数研究并未解决也会增加NT-pro-BNP水平的条件。我们旨在确定无心力衰竭和其他可能影响NT-pro-BNP水平的患者中NT-pro-BNP水平是否与AECOPD结果相关。方法:我们对住院的AECOPD患者进行了回顾性研究,这些患者具有可用的NT-pro-BNP水平和正常的左心室射血分数。我们比较了正常和NT-pro-BNP水平升高的患者,并分析了临床和结局数据。结果:1,420名患者中的167名(11.7%)符合研究标准。总共77%的男性患者和53%的女性患者的NT-pro-BNP水平升高(P = 0.0031)。 NT-pro-BNP水平与COPD严重程度和合并症无关。经对数转换的NT-pro-BNP水平与超声心动图估计的右心室收缩压呈正相关(r = 0.3658; 95%置信区间[CI]:0.2060-0.5067; P <0.0001)。 NT-pro-BNP水平升高的患者更需要重症监护(63%vs 43%; P = 0.0207),住院时间更长(P = 0.0052)。无创正压通气(P = 0.1245)或机械通气(P = 0.9824)或院内死亡率(P = 0.5273)均无差异。结论:AECOPD和NT-pro-BNP水平升高的患者住院时间增加,需要重症监护。根据我们的研究,血清NT-pro-BNP水平不能用作增加死亡率或对此组患者进行有创或无创通气的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号